CTLA4 and melanoma: Clinically, despite the lack of prospective data with a control arm, electroimmunotherapy (ECT plus either anti-CTLA-4 or anti-PD-1) has shown favorable efficacy without apparently increasing toxicities in several advanced melanoma cohorts [33,34,35,36,110].